

05-02-06

*ITW*



CASE ON/4-32572A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 7272 745 2945</u> Express Mail Label Number	<u>May 1, 2006</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1614

FURET ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/07350

FILED: 8 JULY 2003

U.S. APPLICATION NO: 10/520,567 ✓

35 USC §371 DATE: 24 AUGUST 2005

FOR: PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-YL]-  
AMINE DERIVATIVES

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and, since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Lydia T. McNally  
Attorney for Applicants  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898

Date: *May 1, 2006*

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32572A  
APPLICATION NO.  
10/520,567  
APPLICANT  
FURET ET AL.  
FILING DATE  
AUGUST 24, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,306,883					
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	*00 31063	6/2/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	*02 46184	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	*03 049542	6/19/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	01 12621	2/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	01 14375	3/1/01	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	CAPLUS Abstract Accession No. 2000:368337 & WO 00/31063 A1 (G D Searle & Co.) 6/2/00 (abstract)
	AS	
	AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32572A  
APPLICATION NO.  
10/520,567  
APPLICANT  
FURET ET AL.  
FILING DATE  
AUGUST 24, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	01 85700	11/15/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN	01 60816	8/23/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BO	95 19358	7/20/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BP	98 56377	12/17/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	01 62233	8/30/01	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32572A  
APPLICATION NO.  
10/520,567  
APPLICANT  
FURET ET AL.  
FILING DATE  
AUGUST 24, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	98 52940	11/26/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	
	BS	
	BT	



EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS  
AN 2000:368337 CAPLUS  
DN 133:4656  
TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors  
IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.;  
Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.;  
Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,  
Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan;  
Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.;  
Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John  
Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi  
PA G.D. Searle & Co., USA  
SO PCT Int. Appl., 1210 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9915420	A	20020122	BR 1999-15420	19991117
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	US 6423713	B1	20020723	US 2001-918481	20010731
PRAI	US 1998-196623	A	19981120		
	US 1997-47570P	P	19970522		
	US 1998-83670	B2	19980522		
	WO 1999-US26007	W	19991117		
OS	MARPAT 133:4656				
GI					



AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R3CH2COME (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.

IT 271574-63-1P 271574-64-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of heteroarylpyrazole p38 kinase inhibitors by